Imbruvica® (ibrutinib) – Expanded indication, new formulation approval
August 24, 2022 - J&J and AbbVie announced the FDA approval of Imbruvica (ibrutinib), for the treatment of adult and pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.
Top